The company posted $793,000 in product revenues from sales of its OVA1 ovarian cancer test, up 21 percent from $658,000 in the prior-year quarter.
The decision makes OVA1 available to Cigna's 15 million covered customers and brings the total number of lives covered for the test to 167 million.
Launched to commercialize technologies from two leading glycoproteomic researchers, the startup's lead test is a mass spec-based assay for triaging pelvic masses.
Total revenues rose to $774,000 from $699,000 in the year-ago quarter while sales of the company's OVA1 test were up slightly to 1,981 tests from 1,954.
The firm reported total revenues of $708,000, down from $898,000 a year ago, and OVA1 sales volume of 1,884 tests, down 22 percent from 2,418 in Q2 2017.
The firm received notice from Nasdaq that it has failed to meet the requirement that its common stock maintain a minimum closing price bid of $1 per share.
Years after several high-profile failures, activity is up among researchers looking to multi-analyte protein assays for monitoring and detection of the disease.
The investment bank cited disappointing first quarter financial results, a slow uptake to the business, and competitive pressures for the downgrade.
Product revenues were $613,000, down from $678,000 in Q1 2017, while service revenues were $36,000, down from $48,000 the year before.
The company will offer 10 million shares of common stock at $1.00 per share and 50,000 shares of Series B Convertible Preferred Stock at $100.00 per share.